Key facts
- It has raised $194.3M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($194.3M) in Feb 2024.
- BioAge Labs has filed 1 Form D with the SEC, most recently Feb 2024 ($194.4M sold to 32 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for BioAge Labs
Create free account
No card required
Funding rounds
2 roundsFeb 2024Later Stage VC (Series D)$194.3M▮
Jan 2019Accelerator/Incubator—▮
About BioAge Labs
- Industry
- Drug Discovery
PA Mark — not yet priced
BioAge Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in BioAge Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on BioAge Labs in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.